Predictors of early response to infliximab in patients with ulcerative colitis

Απλή σελίδα τεκμηρίου
dc.contributor.authorFerrante, M.en
dc.contributor.authorVermeire, S.en
dc.contributor.authorKatsanos, K. H.en
dc.contributor.authorNoman, M.en
dc.contributor.authorVan Assche, G.en
dc.contributor.authorSchnitzler, F.en
dc.contributor.authorArijs, I.en
dc.contributor.authorDe Hertogh, G.en
dc.contributor.authorHoffman, I.en
dc.contributor.authorGeboes, J. K.en
dc.contributor.authorRutgeerts, P.en
dc.date.accessioned2015-11-24T18:57:16Z
dc.date.available2015-11-24T18:57:16Z
dc.identifier.issn1078-0998-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19148
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnti-Inflammatory Agents/*therapeutic useen
dc.subjectAntibodies, Monoclonal/*therapeutic useen
dc.subjectAzure Stainsen
dc.subjectChilden
dc.subjectColitis, Ulcerative/*drug therapy/pathologyen
dc.subjectColonoscopyen
dc.subjectFemaleen
dc.subjectGastrointestinal Agents/*therapeutic useen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.titlePredictors of early response to infliximab in patients with ulcerative colitisen
heal.abstractBACKGROUND: Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response. METHODS: The first 100 UC patients (45 female; median age, 37.9 years) who received IFX at a single center were included. Eighty-four patients received 5 mg/kg IFX, and 37 patients received a 3-dose IFX induction at weeks 0, 2, and 6. The Mayo endoscopic subscore, assessed by sigmoidoscopy before inclusion, was 1, 2, and 3 in 5%, 52%, and 43% of patients, respectively. Sixty percent had pancolitis, 63% were on concomitant immunosuppressive therapy, 9% were active smokers, 64% had C-reactive protein > or =5 mg/dL, and 44% were pANCA+/ASCA-. Five patients received IFX because of severe acute colitis refractory to intravenous corticosteroids. RESULTS: Early complete and partial clinical responses were observed in 41% and 24% of patients. Patients with early clinical response were significantly younger than nonresponders (median age, 35.7 versus 41.6 years, P = 0.041). Patients who were pANCA+/ASCA- had a significantly lower early clinical response (55% versus 76%; odds ratio [OR] = 0.40 (0.16-0.99), P = 0.049). Concomitant immunosuppressive therapy and the use of an IFX induction scheme did not influence early clinical response. Only 1 of 5 patients who received IFX for acute steroid-refractory colitis required colectomy within 2 months. CONCLUSIONS: IFX is an efficient therapy in UC, as shown by 65% early clinical response. A pANCA+/ASCA- serotype and an older age at first IFX infusion are associated with a suboptimal early clinical response.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1002/ibd.20054-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17206703-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/ibd.20054/asset/20054_ftp.pdf?v=1&t=h0tajn0r&s=9017c15cd0cce21a83c22a46b24d9d06aede5412-
heal.journalNameInflamm Bowel Disen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ